Biocryst Pharmaceuticals, Inc.
A biopharmaceutical company that develops medicines for rare diseases, BioCryst's flagship product is Orladeyo, an oral once-daily pill that prevents attacks of hereditary angioedema, a rare genetic condition causing sudden, painful swelling. Founded in 1986 in Birmingham, Alabama, the name blends "bio" with "cryst," a nod to the X-ray crystallography technique its scientists use to design drugs at the molecular level. The company also markets RAPIVAB, an antiviral treatment for influenza.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| RA Capital Management, L.P. | 13G/APassive | 6.2% | 15.83M | Aug 14, 2026 |
| Peter Kolchinsky | 13G/APassive | 6.2% | 15.83M | Aug 14, 2026 |
| Rajeev Shah | 13G/APassive | 6.2% | 15.83M | Aug 14, 2026 |
| RA Capital Healthcare Fund, L.P. | 13G/APassive | 6.2% | 15.83M | Aug 14, 2026 |
| STATE STREET CORPORATION | 13GPassive | 6% | 15.19M | Aug 7, 2026 |
| Vanguard Capital Management | 13GPassive | 5.16% | 12.96M | Apr 29, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 26, 2026 |
| Deerfield Mgmt, L.P. | 13G/APassive | 6.81% | 14.34M | Feb 12, 2026 |
| Deerfield Management Company, L.P. | 13G/APassive | 6.81% | 14.34M | Feb 12, 2026 |
| Deerfield Partners, L.P. | 13G/APassive | 6.81% | 14.34M | Feb 12, 2026 |